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Introduction
Endocrine therapy forms the backbone in the management of 
metastatic-hormone-receptor-positive (HR+) breast cancer. 
In the recent years, novel targeted approaches when combined 
with endocrine therapy have shown to improve progression-
free survival (PFS). The BOLERO2, a phase-3, randomized, 
controlled trial of women with advanced HR+ HER2 non-
amplified (HER2–) metastatic breast cancer (MBC), demon-
strated a statistically significant improvement in (PFS) in 
women who were treated with the combination of everolimus 
plus exemestane as compared to exemestane alone.1 The com-
bination was approved in the United States for treatment 
HR+ HER2-MBC after failure of treatment with an aro-
matase inhibitor (AI) in July 2012.2 Since 2015, the US Food 
and Drug Administration (FDA) has approved 3 CDK4/6 
inhibitors, palbociclib, ribociclib, and abemaciclib, in combi-
nation with endocrine therapy as first line or subsequent lines 
of therapy for HR+ HER2-MBC after their respective 
phase-3 clinical trials showed significant improvement in PFS 
with these combination as compared to endocrine therapy 
alone in both front and subsequent line therapies.3-11 Current 
paradigm favors the use of CDK4/6 inhibitors prior to everoli-
mus in the treatment sequence, although optimal sequence of 
therapy has not been established. Breast tumor biology evolves 
with treatment, acquiring genetic changes and developing 
resistance to therapy.12 The tumor biology and resistance pat-
tern of the BOLERO2 cohort could be significantly different 
from present day HR+ MBC cohorts who are resistant to 
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CDK4/6 inhibition. Multiple preclinical studies have sug-
gested interactions between the PI3K/Akt/mTOR pathway 
and the downstream Cyclin D/CDK4/6/Rb pathway. It raises 
the possibility of cross-resistance between an mTOR inhibitor 
and CDK4/6 inhibitors while other studies have shown that 
cell cycle inhibition is associated with a compensatory activa-
tion of mTOR/AKT pathway, increased Cyclin D expression 
leading to a leak in the cell cycle block and thus resistance to 
CDK4/6 inhibitor.13-20 Currently, there are no clinical data on 
the efficacy of everolimus combinations in HR+ HER2-
MBC after they have progressed on CDK4/6 inhibitor-based 
combinations. The objective of this study is to find the efficacy 
of everolimus combinations among HR+ HER2-MBC 
patients after progression on palbociclib combinations.
Methods
This is a retrospective, 2-institute review of HR+ HER2-MBC 
patients from January 2015 to March 2018 treated with everoli-
mus combinations after progression on palbociclib combinations. 
MBC patients with biopsy proven estrogen receptor-positive 
(ER+) HER2– carcinoma who received palbociclib combina-
tions prior to everolimus combinations were eligible for the study. 
Based on the American Society of Clinical Oncology/College of 
American Pathologists guidelines, breast carcinomas with 1% of 
more immuno-reactive tumor cells for ER on immunohisto-
chemistry (IHC) or an Allred score of 3 or more were considered 
as ER+ breast cancer.21 Similarly, 0 or 1+ scores of HER2 stain 
on IHC or average HER2 copy number <4.0 signals per cell 
(single probe assay) or HER2/CEP17 ratio <2.0 and average 
HER2 copy number <4.0 signals per cell (dual-probes assay) 
using fluorescence in situ hybridization (FISH) was considered 
HER2 non-amplified.21 Patients with primary ER+ carcinoma 
whose biopsy of subsequent metastatic tissue was ER– were eligi-
ble for study only if these patients continued to receive endo-
crine-based therapy for the metastatic disease based on providers’ 
clinical judgment. Women who received everolimus or palboci-
clib for less than 4 weeks were excluded to ensure minimum 
meaningful exposure to both drugs in enrolled patients. Any 
starting dose of everolimus was allowed. Primary end point of the 
study was the analysis of median PFS and secondary end points 
were to calculate the objective response rate (ORR), clinical ben-
efit ratio (CBR), and overall survival (OS) of these patients on 
everolimus combinations. Progression-free survival was defined 
as the time from the initiation of everolimus to the date of death 
or progression, whichever occurs first. Progression was deter-
mined by the treating physicians based on radiological, biochemi-
cal, and/or clinical criteria. Best overall response rates were 
determined based on available radiological data. The objective 
response rate was defined as the rate of any complete or partial 
responses (CR or PR). Clinical benefit (CB) was defined as CR 
or PR or stable disease (SD) of at least 6 months.
Separate institutional review board (IRB) approvals were 
obtained at Roswell Park Comprehensive Cancer Center 
(Roswell Park) and University of Pittsburgh Medical Center 
(UPMC) prior to data extraction. Preliminary patients’ lists 
were generated by computer-based queries by respective bioin-
formatics resources available at these centers. Chart review and 
eligibility assessment were performed by A.D. (Roswell Park) 




Initial query on electronic medical records from Roswell Park 
main campus and a satellite location yielded 31 eligible patients, 
out of which 7 patients were excluded: 4 patients received 
everolimus prior to palbociclib, 1 patient received everolimus 
for less than 4 weeks, 1 patient received insurance approval for 
everolimus but never used it and last patient’s subsequent 
biopsy showed triple-negative breast cancer though she had 
ER+ primary breast cancer in the past. Similarly, out of 27 
initial patients from UPMC, 10 were excluded: 5 patients 
received everolimus for less than 4 weeks, 4 patients received 
everolimus prior to palbociclib and 1 patient received palboci-
clib for less than 4 weeks. Among those 6 ineligible patients 
who received everolimus for less than 4 weeks, everolimus was 
discontinued due to progression of disease in 3 patients, intol-
erance in 1, and data were immature (less than 4 weeks) for the 
remaining 2 patients. Full data extraction and analysis was per-
formed on a total of 41 patients.
Patients’ characteristics
Median age of the patients was 61 years (range: 33-87). Thirty-
eight patients had biopsy proven ER+ MBC while the remain-
ing 3 patients had ER+ breast cancer in their primary biopsy 
but ER– in the biopsy of the metastatic site. These patients 
were treated by their physicians as ER+ breast cancers based 
on the clinical judgment which appeared to be influenced by 
natural history of disease and suboptimal biopsy tissue from 
the metastatic site. These patients were also enrolled in the 
study. Around 72% of the women had progesterone-receptor-
positive tumor, all of the women had HER2– (56% by IHC 
alone, remaining confirmed by FISH) disease. Median disease-
free interval (duration between diagnosis of primary breast 
cancer and the recurrence) was 60 months (4, 276). Twenty-six 
out of 41 patients (66%) had received adjuvant therapy (chem-
otherapy and/or hormonal therapy). Out of 14 patients who 
did not receive any adjuvant chemotherapy and/or hormonal 
therapy, 8 were de novo metastatic disease. About 77% patients 
had demonstrated prior sensitivity to endocrine therapy, which 
was defined as at least 24 months of endocrine therapy before 
recurrence in the adjuvant setting or a complete or partial 
response or stabilization of disease for at least 24 weeks on 
endocrine therapy for advanced disease. About 61% women 
had visceral disease, 90% of the women had bone metastases, 
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and 32% had 3 or more organs involved with metastases. 
Almost 95% had prior non-steroidal AIs, 41% had prior 
exemestane, and 66% had prior tamoxifen. Around 71% had 
received prior chemotherapy for breast cancer, of which 45% 
had received it in adjuvant/neoadjuvant settings while the 
remainder received chemotherapy in the metastatic or in both 
settings. Median number of therapies, counting chemotherapy, 
and hormonal therapy, prior to everolimus was 4 (1, 11), and 
83% had 3 or more prior chemotherapy or hormonal therapies 
prior to everolimus. Median order of palbociclib was 4th (1st, 
11th) in the sequence of therapies, and median duration of 
palbociclib-based therapies was 7 months (2, 24). Median 
duration of everolimus combinations was 3.2 months (0.9, 
15.4). See Table 1 for patients’ characteristics of study cohort.
Efficacy of everolimus-based therapy
Out of 41 patients, 27 patients had primary events (25 progres-
sions, 2 deaths) on everolimus therapy. Out of 25 patients who 
progressed, 23 had radiographic evidence of progression. The 
remaining 2 patients were considered to have progressed by 
their physicians based on clinical and laboratory evidence 
(increasing tumor markers and new skin and breast mass; 
increasing tumor markers and decline in overall performance 
status, patient referred to hospice). Kaplan-Meier estimates 
showed a median PFS of 4.2 months (95% confidence interval 
[CI]: 3.2-6.2) (Figure 1). At a median follow up of 7.4 months 
(0.9, 23.2), 10 patients had died. The median OS was 
18.7 months (95% CI: 9.5 to not reached) (Figure 2). About 
17.1% of women had partial response, 36.6% had stable disease, 
31.7% had progressive disease, and 14.6% had not reached a 
response yet. About 17.1% had objective responses on everoli-
mus combinations, 63.4% did not have any objective responses 
while 19.5% had not reached objective responses at the time of 
data extraction. Median time to objective response was 
3.1 months (2.0, 4.2). By the time of final data extraction, 7 
(17.1%) patients had achieved clinical benefit with everolimus 
combinations. Median duration of clinical benefit was 8 months 
(7, 16) with mentionable duration of 13 and 16 months in 2 
women. Twenty-four patients failed to achieve clinical benefit, 
while data were premature for remaining 10 patients, 5 of which 
already had stable diseases on restaging scans. See Table 2 for 
response rates of study cohort.
Discussion
This study has provided clinical efficacy data of everolimus-
based combination in HR+ HER2-MBC patients, who have 
progressed on palbociclib-based combinations. The median 
PFS of our study cohort was 4.2 months (95% CI: 3.2-6.2) 
while that of the everolimus plus exemestane arm of the 
BOLERO2 was 6.9 months (95% CI: 6.4-8.1).1 The median 
OS of our study cohort was 18.7 months (95% CI: 9.5 to not 
reached), while that of the everolimus cohort of BOLERO2 
was 31.0 months (95% CI: 28.0-34.6).22 About 17.1% of 
women in our study cohort had an objective response and 
same percentage achieved predefined clinical benefit. About 
9.5% women in the everolimus cohort of BOLERO2 had an 
objective response. The patient and disease characteristics 
between this study cohort and the everolimus cohort of 
BOLERO2 are comparable in terms of age, disease-free inter-
val, prior sensitivity to endocrine therapy, and disease burden. 
This study cohort received a median of 4 lines of therapy prior 
to an everolimus combination as compared to a median of 3 
lines of therapy on the BOLERO2 cohort. About 83% women 
in the study cohort received 3 or more lines of therapy prior to 
the everolimus combination while only 54% women in the 
everolimus plus exemestane cohort of BOLERO2 had 3 or 
more lines of prior therapy. Thus, our study cohort had more 
heavily pretreated women and everolimus combinations were 
initiated in later stages of the MBC therapy as compared to 
BOLERO2 cohorts. In addition, our cohort received up to 
23.6 months (median 7.0 months) of palbociclib therapy in the 
earlier part of the MBC therapy. Thus, compared to everoli-
mus cohort of BOLERO2, women on our cohort received 
longer duration of prior endocrine-based therapy due to the 
use of palbociclib.
Given the clear PFS benefit in front-line settings as com-
pared to an AI and relatively good side effect profile, CDK4/6 
inhibitors are being used as first or second line of therapy, and 
everolimus combinations are used later in the sequence of ther-
apies for HR+ HER2-MBC. Whether this sequence is the 
best approach will become clearer after the maturity of OS data 
from the first-line CDK4/6 inhibitors trial and the BOLERO4 
trial.4-6,23 A randomized study comparing the sequence of 
CDK4/6 inhibition followed by mTOR inhibition versus the 
opposite may provide a definite answer and some biomarkers 
to help guide clinicians.
A retrospective study design, a relatively small sample size, 
and nonstandard response assessments are the major limita-
tions of this study. In addition, performance status could not be 
analyzed in this retrospective study due to the inconsistent 
documentation in the medical record. Unlike the BOLERO2 
where all patients in the everolimus cohort received everolimus 
plus exemestane, our cohort contained patients treated with 
everolimus plus any AI or fulvestrant. Detail information of the 
endocrine therapy partner of everolimus was not obtained dur-
ing the chart review. However, 41% of the patients had prior 
exemestane in our cohort, 95% had prior letrozole or anastro-
zole, and 66% had prior fulvestrant or tamoxifen. Everolimus 
toxicity and dose reduction information was not obtained in 
this study. The results of the BOLERO2 trial has been used as 
a reference for the efficacy of everolimus combinations in the 
pre-CDK4/6 inhibitor era in this study. The real-world data 
may differ from the data of clinical trials as the clinical trials 
triage fitter patients with lesser comorbid conditions and mon-
itor patients more closely. We did not obtain data of everolimus 
4 Breast Cancer: Basic and Clinical Research 
Table 1. Patients’ characteristics of study cohort.
PATIENTS’ CHARACTERISTICS STUDY COHORT (N = 41)
Age (year)
 Median (range) 61 (33-87)
Breast cancer type
 De novo 8
 Recurrence 33
Disease-free interval (months)
 Median (range) 60 (4-276)
Received adjuvant therapy (%) 66
Previous sensitivity to endocrine therapy (%) 77





Number of metastatic sites (%)
 1 36
 2 32
 3 or more 32
Previous treatment with letrozole or anastrozole (%) 95
Previous treatment with exemestane (%) 41
Previous treatment with any antiestrogen therapy (tamoxifen or fulvestrant) 66
Chemotherapy prior to everolimus (%) 71
Chemotherapy settings
 Neoadjuvant/adjuvant therapy 32
 Metastatic disease with or without neoadjuvant/adjuvant therapy 39
Number of therapies prior to everolimus
 Median (range) 4 (1-11)
 1 (%) 5
 2 (%) 12
 3 or more (%) 83
Palbociclib’s position in the sequence
 Median (range) 4 (1-11)
Palbociclib duration (months)
 Median (range) 7 (2-24)
Everolimus duration (months)
 Median (range) 3.2 (0.9-15.4)
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combination used in the pre-CDK4/6 inhibitor era at our 
institutions in this study. However, there are some published 
real-world data on the efficacy of everolimus combination in 
HR+ HER2- MBC after the progression of an AI. Hao et al24 
performed a chart review of 192 ER+ MBC patients from 
community-based oncology practices, who received everolimus 
combination after progression on an AI, showing a median 
PFS was 9.1 months. Similarly, Xie et al25 performed a chart 
review of 243 ER+ MBC patients from community-based 
oncology practices, who had received everolimus combination 
after progression on an AI, demonstrating a median PFS of 
8.5 months.
Our study is the first to provide evidence of clinical benefit 
of targeting mTOR pathway postprogression on CDK4/6 
inhibitor combination. Despite limitations of our study, we 
show that everolimus remains a potential treatment option in 
the current treatment climate with small percentage of patients 
obtaining prolonged clinical benefit.
Conclusion
Our study, for the first time, provides clinical data showing 
benefit of using everolimus combinations postprogression on 
CDK4/6 inhibitor treatment in patients with HR+ MBC. 
The combination was associated with a modest PFS of 
4.2 months and ORR of 17.1%. Only 7 out of 41 women 
achieved clinical benefit, but 2 of them had prolonged benefit 
of 13 and 16 months. These results will assist clinicians in hav-
ing an informed conversation with patients when everolimus 
therapy is being considered after CDK4/6 inhibition therapy.
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Figure 1. Kaplan-Meier estimates show a median progression-free 
survival of 4.2 months (95% CI: 3.2-6.2). CI indicates confidence interval.
Figure 2. Kaplan-Meier estimates show a median overall survival of 
18.7 months (95% CI: 9.5 to not reached). CI indicates confidence 
interval.
Table 2. Tumor response on everolimus-based therapy.
RESPONSES STUDY COHORT (N = 41)
Best overall response (%)
 Complete response 0
 Partial response 17.1
 Stable disease 36.6
 Progressive disease 31.7
 Unknown or too early 14.6
Objective response rate (%) 17.1
Clinical benefit rate (%) 17.1
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